Identification of novel antigens that protect against systemic meningococcal infection

Vaccine

Volumn 23, Issue 32, 2005, Pages 4136-4141

  Sun, Yaohui ^a   Li, Yanwen ^a   Exley, Rachel M ^a   Winterbotham, Megan ^a   Ison, Catherine ^a   Smith, Harry ^b   Tang, Christoph M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Neisseria meningiditis; Protein; Vaccine

Indexed keywords

A 22; BZ 169; C 311; CARBENICILLIN; EXBB PROTEIN; KANAMYCIN; LACTATE PERMEASE; MC 58; NGP 165; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; YH 102;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG TARGETING; IMMUNE RESPONSE; INFECTION PREVENTION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

BACTERIAL PROTEINS; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; VACCINES, SYNTHETIC;

EID: 20444474139     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.03.015     Document Type: Article

References (30)

1. I.M. Feavers ABC of meningococcal diversity Nature 404 2000 451 452
2. A. van Deuren, M.P. Brandtzaeg, and J.W. van der Meer Update on meningococcal disease with emphasis on pathogenesis and clinical management Clin Microbiol Rev 13 2000 144 166
3. C.K. Fairley, N. Begg, R. Borrow, A.J. Fox, D.M. Jones, and K. Cartwright Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants J Infect Dis 174 1996 1360 1363
4. M. Ramsay, E. Kaczmarski, M. Rush, R. Mallard, P. Farrington, and J. White Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales Commun Dis Rep CDR Rev 7 1997 49 54
5. J. Finne, D. Bitter-Suermann, C. Goridis, and U. Finne An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues J Immunol 138 1987 4402 4407
6. J. Finne, M. Leinonen, and P.H. Makela Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis Lancet 2 1983 355 357
7. L. Jodar, I.M. Feavers, D. Salisbury, and D.M. Granoff Development of vaccines against meningococcal disease Lancet 359 2002 1499 1508
8. J.S. Plested, S.L. Harris, J.C. Wright, P.A. Coull, K. Makepeace, and M.A. Gidney Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia J Infect Dis 187 2003 1223 1234
9. M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arico, and M. Comanducci Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Science 287 2000 1816 1820
10. Z. Hindle, S.N. Chatfield, J. Phillimore, M. Bentley, J. Johnson, and C.A. Cosgrove Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers Infect Immun 70 2002 3457 3467
11. C.O. Tacket, M.B. Sztein, G.A. Losonsky, S.S. Wasserman, J.P. Nataro, and R. Edelman Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans Infect Immun 65 1997 452 456
12. Y.H. Sun, S. Bakshi, R. Chalmers, and C.M. Tang Functional genomics of Neisseria meningitidis pathogenesis Nat Med 6 2000 1269 1273
13. H. Tettelin, N.J. Saunders, J. Heidelberg, A.C. Jeffries, K.E. Nelson, and J.A. Eisen Complete genome sequence of Neisseria meningitidis serogroup B strain MC58 Science 287 2000 1809 1815
14. M. Virji, H. Kayhty, D.J. Ferguson, C. Alexandrescu, J.E. Heckels, and E.R. Moxon The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells Mol Microbiol 5 1991 1831 1841
15. Y. Li, Y.H. Sun, C. Ison, M.M. Levine, and C.M. Tang Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci Infect Immun 72 2004 345 351
16. S.L. Chiang, J.J. Mekalanos, and D.W. Holden In vivo genetic analysis of bacterial virulence Annu Rev Microbiol 53 1999 129 154
17. G.D. Biswas, J.E. Anderson, and P.F. Sparling Cloning and functional characterization of Neisseria gonorrhoeae tonB, exbB and exbD genes Mol Microbiol 24 1997 169 179
18. I. Stojiljkovic, and N. Srinivasan Neisseria meningitidis tonB, exbB, and exbD genes: Ton-dependent utilization of protein-bound iron in Neisseriae J Bacteriol 179 1997 805 812
19. M.C. Maiden, J.A. Bygraves, E. Feil, G. Morelli, J.E. Russell, and R. Urwin Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms Proc Natl Acad Sci USA 95 1998 3140 3145
20. D. Martin, N. Cadieux, J. Hamel, and B.R. Brodeur Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection J Exp Med 185 1997 1173 1183
21. E. Rosenqvist, E.A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, and A. Klem Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine Infect Immun 63 1995 4642 4652
22. B. Haneberg, R. Dalseg, E. Wedege, E.A. Hoiby, I.L. Haugen, and F. Oftung Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans Infect Immun 66 1998 1334 1341
23. E. Rosenqvist, E.A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, and A. Klem Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine Infect Immun 63 1995 4642 4652
24. I. Goldschneider, E.C. Gotschlich, and M.S. Artenstein Human immunity to the meningococcus. I. The role of humoral antibodies J Exp Med 129 1969 1307 1326
25. K.J. Oliver, K.M. Reddin, P. Bracegirdle, M.J. Hudson, R. Borrow, and I.M. Feavers Neisseria lactamica protects against experimental meningococcal infection Infect Immun 70 2002 3621 3626
26. J.A. Welsch, G.R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D.M. Granoff Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity J Infect Dis 188 2003 1730 1740
27. C.T. Sacchi, A.M. Whitney, T. Popovic, D.S. Beall, M.W. Reeves, and B.D. Plikaytis Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States J Infect Dis 182 2000 1169 1176
28. A. van der Ende, C.T. Hopman, and J. Dankert Multiple mechanisms of phase variation of PorA in Neisseria meningitidis Infect Immun 68 2000 6685 6690
29. J. Parkhill, M. Achtman, K.D. James, S.D. Bentley, S.R. Churcher, and G. Klee Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491 Nature 404 2000 502 506
30. R. Grifantini, E. Bartolini, A. Muzzi, M. Draghi, E. Frigimelica, and J. Berger Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays Nat Biotechnol 20 2002 914 921